Loading
NYSEHealthcareMedical - Devices
Latest quote
$102.92
+$0.07 · +0.07%
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Previous close
$102.92
+$0.07 · +0.07%
Regular session · ET · Market data may be delayed.
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Day range
Current $102.92
52-week range
Current $102.92
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
76
Undervalued
Sentiment
61
Bullish
Risk
30
Moderate Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Day range
Current $102.92
52-week range
Current $102.92
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 1.33B USD | 1.36B USD | 1.31B USD | 1.17B USD | 993.2M USD |
| Cost of goods sold | 590.44M USD | 582.28M USD | 597.14M USD | 545.79M USD | 462.43M USD |
| Gross profit | 743.59M USD | 778.55M USD | 711.92M USD | 622.87M USD | 530.77M USD |
| Research and development | 59.77M USD | 69.42M USD | 63.04M USD | 58.63M USD | 55.2M USD |
| Selling, general, and administrative | 442.42M USD | 422.05M USD | 420.82M USD | 373.95M USD | 332.2M USD |
| Operating expenses | 502.19M USD | 556.73M USD | 547.03M USD | 466.84M USD | 450.02M USD |
| Interest expense | 28.7M USD | 9.75M USD | 13.02M USD | 14.63M USD | 17.12M USD |
| Depreciation and amortization | 155.72M USD | 108.89M USD | 88.62M USD | 84.81M USD | 86.55M USD |
| Operating income | 241.4M USD | 221.82M USD | 164.88M USD | 156.03M USD | 80.75M USD |
| Net income | 97.31M USD | 167.68M USD | 117.56M USD | 115.4M USD | 43.38M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$108.6
5.52% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 3, 2012 | 2:1 | — | — |
Stock split | Jan 11, 1993 | 2:1 | — | — |
Effective Dec 3, 2012
2:1
Effective Jan 11, 1993
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Mid-Cap ETFIJH145.1M0.11%126.02B USD0.05%$75.85+0.13%
iShares Russell 2000 ETFIWM124.46M0.15%80.51B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI123.79M0.01%2.3T USD0.03%$379.73-0.32%
Vanguard Morningstar Small-Cap ETFVB89.38M0.05%183.4B USD0.03%$300.01+0.05%
Vanguard Extended Market ETFVXF45.79M0.05%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Growth ETFIWO42.53M0.29%14.7B USD0.24%$377.54+0.12%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY35.14M0.13%26.57B USD0.23%$691.52+0.13%
Vanguard Morningstar Small-Cap Value ETFVBR28.38M0.04%68.3B USD0.05%$247.11+0.08%iShares Core S&P Mid-Cap ETFIJHiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P MIDCAP 400 ETF TrustMDYVanguard Morningstar Small-Cap Value ETFVBRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
